A number of tools are available to assess disease severity and progression in patients with peripheral neuropathies such as CIDP. Gain a better understanding of four of these tools.
David R. Cornblath received his MD from Case Western Reserve University and completed his residency and fellowship at the Hospital of the University of Pennsylvania under Prof. A.K. Asbury.
Jonathan S. Katz, MD
Forbes Norris MDA/ALS Research Center at the California Pacific Medical Center in San Francisco, California
Jonathan S. Katz, MD
Forbes Norris MDA/ALS Research Center at the California Pacific Medical Center in San Francisco, California
MMN
Jonathan S. Katz, MD, is the Director, Forbes Norris MDA/ALS Research Center at the California Pacific Medical Center in San Francisco, California.
Mel Berger, MD, PhD
Medical Research Strategy, CSL Behring
Mel Berger, MD, PhD
Medical Research Strategy, CSL Behring
CIDP
Mel Berger is a Senior Director, Medical Research Strategy at CSL and Adjunct Professor of Pediatrics and Pathology, Case Western Reserve University. He earned his undergraduate, medical and PhD (in Biochemistry) degrees at Case Western Reserve University in Cleveland.
Richard A. Lewis, MD
Cedars-Sinai Medical Center, Los Angeles, CA, USA
Richard A. Lewis, MD
Cedars-Sinai Medical Center, Los Angeles, CA, USA
CIDP
GBS
MMN
Richard A. Lewis, MD is Professor of Neurology at Cedars-Sinai Medical Center in Los Angeles, California where he directs the EMG laboratory and co-directs the neuromuscular clinical program.